

Statement of Advice:

**follitropin delta 12 micrograms, 36 micrograms and 72 micrograms solution
for injection (Rekovel®) (No: 1269/17)**

Ferring Pharmaceuticals Ltd

07 July 2017

ADVICE: in the absence of a submission from the holder of the marketing authorisation

follitropin delta (Rekovel®) is not recommended for use within NHS Scotland.

Indication under review: Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman,
Scottish Medicines Consortium**